Stockscreener 앱 받기
359.27
0.00%
0.010
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings - Benzinga
Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock - Benzinga
How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In - MedCity News
Alnylam EVP Pushkal Garg sells $547k in stock By Investing.com - Investing.com South Africa
Alnylam EVP Pushkal Garg sells $547k in stock - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 9,577 Shares - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock - MarketBeat
JPM preannouncements: Why Alnylam and Sarepta lost, but Day One won - MSN
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback? - Yahoo Finance
JPM26: 2025 a “breakout year” for rare disease biotechs - Yahoo Finance
Aug Gainers: What is ORLYs book value per shareQuarterly Profit Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Tokio Marine Asset Management Co. Ltd. Takes $2.03 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld MedTech
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short - TechStock²
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down After Analyst Downgrade - MarketBeat
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. - MarketBeat
JPM Kicks Off With Alnylam In the Red; But Others Surge - Investor's Business Daily
What's Going On With Alnylam Pharma Stock Monday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam (ALNY) Projects Strong Revenue Growth for 2026 Amidst TT - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $529.00 by Analysts at Bank of America - MarketBeat
B of A Securities Lowers Price Target for ALNY While Maintaining Buy Rating | ALNY Stock News - GuruFocus
Needham raises Alnylam Pharmaceuticals stock price target on strong 2026 guidance - Investing.com UK
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $529.00 - MarketBeat
Alnylam Pharmaceuticals (ALNY) Receives Rating Reaffirmation and Price Target Increase | ALNY Stock News - GuruFocus
Alnylam stock price target lowered to $529 by BofA on Q4 revenue miss - Investing.com UK
Nisa Investment Advisors LLC Has $5.53 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Raymond James reiterates Outperform rating on Alnylam stock at $472 target - Investing.com UK
Alnylam Pharmaceuticals stock rises as Goldman Sachs reiterates Buy rating By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unveiling a 22.96% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation - Nasdaq
Los Angeles Daily NewsAlnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact - FinancialContent
Alnylam Launches “ Alnylam 2030 ” Strategy to Drive Next Era of Growth and Patient Impact - Business Wire
Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)? - simplywall.st
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 19% ROE Better Than Average? - Yahoo Finance
Alnylam raises 2025 revenue guidance to $3.05B amid robust AMVUTTRA ATTR-CM launch momentum - MSN
ALNYLAM PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $ALNY Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 Sentiment & Safe Entry Trade Signal Reports - ulpravda.ru
Is It Too Late To Consider Alnylam Pharmaceuticals (ALNY) After Its 67% One Year Surge - simplywall.st
Trading the Move, Not the Narrative: (ALNY) Edition - Stock Traders Daily
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 | CAGR 23.1% - openPR.com
SG Americas Securities LLC Purchases Shares of 31,850 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock testing key supportEarnings Risk Summary & Capital Efficient Trade Techniques - ulpravda.ru
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As It Previews New Five Year Plan And Revenue Outlook - simplywall.st
How buybacks impact Alnylam Pharmaceuticals Inc. stock valueJuly 2025 Chart Watch & Fast Entry and Exit Trade Plans - ulpravda.ru
Truist Financial Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $530.00 - MarketBeat
Is Alnylam Pharmaceuticals Inc. stock safe for conservative investorsWeekly Trend Summary & Reliable Volume Spike Alerts - ulpravda.ru
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Europe Gene Therapy Market to hit US$ 8,780.77 Million by 2033 | - openPR.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Oppenheimer - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Seems To Use Debt Quite Sensibly - Yahoo Finance
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewswire Inc.
Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2026 world cup usa national team group stage young talents build up play winner prediction statistical analysis - ulpravda.ru
Bernstein lowers Alnylam stock price target to $491 on slowing Amvuttra sales - Investing.com UK
1.63%
1.35%
자본화:
|
볼륨(24시간):